Houston-based Moleculin Biotech Inc., a clinical stage pharmaceutical company, has gained fast-track U.S. Food and Drug Administration approval for ...
News
- Houston drug maker targeting cancer tumors gains special FDA approval
- San Antonio wound-care company files for initial public offering
San Antonio wound-care company Acelity, formerly known as Kinetic ... That year, the company completed the sale of LifeCell Corp., a biomedical ...
- EPS for Celcuity Inc. (CELC) Expected At $-0.22 on May, 13
... Studies at the 2018 San Antonio Breast Cancer Symposium Evaluating HER2-Negative Breast Cancer Tumors with ... “Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center – Business ...
- Anticipated $-0.22 EPS for Celcuity Inc. (CELC) on May, 13
... Stocks Year-to-Date – Investing News Network” published on December 04, 2018, “Biotech startup Celcuity raises ... San Antonio Breast Cancer Symposium Evaluating HER2-Negative Breast Cancer Tumors with Hyperactive and ...
- Plans for Chrysler site inching forward
The Waymaker Group LLC of San Antonio received a nine-month contract on April 1 at $22,500 per month. The project ... Biotechnology/life science.